Glycogen-Rich Clear Cell Carcinoma of the Breast: Report of Two New Cases and an Updated Literature Review
GRCC is heterogeneous and should not be regarded as a single clinicopathologic entity within invasive breast carcinoma of no special type or assumed to have a uniform prognosis. Management should be biomarker-guided, as illustrated by these cases. The role of targeted and immune therapies in GRCC warrants multi-institutional studies.
Authors
- S. Beslija (ORCID: https://orcid.org/0000-0002-3066-3871)
- Nermina Ibišević
- Zoran Gatalica
- Timur Cerić (ORCID: https://orcid.org/0000-0001-5478-8057)
- Semir Vranić (ORCID: https://orcid.org/0000-0001-9743-7265)
- Jasmina Redžepagić
- Faruk Skenderi (ORCID: https://orcid.org/0000-0002-2200-354X)
Institutions
- University of Sarajevo (BA)
- Sarajevo School of Science and Technology (BA)
- Clinical Center University of Sarajevo (BA)
- Qatar University (QA)
Publication Details
- Journal
- Acta Medica Academica
- Published
- 2025-11-20
- DOI
- https://doi.org/10.5644/ama2006-124.487
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00